Loading patent…
AssigneesIP2Ipo Innovations Limited, ID Pharma Co., Ltd.
InventorsEric Walter Frederick Wolfgang Alton, Uta Griesenbach, Kamila Malgorzata Pytel, Michael Christian Paul-Smith, Ian Andrew Pringle, Stephen Charles Hyde, Deborah Rebecca Gill, Lee Adrian Davies, Alan Christopher Boyd, Gerard McLachlan, Makoto Inoue
Estimating the term…
This invention relates to lentiviral gene transfer vectors pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, comprising a promoter and a transgene; and methods of making the same. The present invention also relates to the use of said vectors in gene therapy, particularly for the treatment of respiratory tract diseases such as Cystic Fibrosis (CF).
A lentiviral vector pseudotyped with hemagglutinin-neuraminidase (HN) and fusion (F) proteins from a respiratory paramyxovirus, wherein said lentiviral vector comprises a hybrid human CMV enhancer/EF1a (hCEF) promoter and a transgene, and wherein the lentiviral vector lacks an intron positioned between said promoter and said transgene.
Dependencies are inferred from the claim text.